Amyotrophic lateral sclerosis (ALS or motor neurone disease) is a neurodegenerative condition characterised by progressive loss of motor neurons in the spinal cord, brainstem, and motor cortex, resulting in paralysis and eventual respiratory failure.
Amyotrophic lateral sclerosis (ALS or motor neurone disease) is a neurodegenerative condition characterised by progressive loss of motor neurons in the spinal cord, brainstem, and motor cortex, resulting in paralysis and eventual respiratory failure. Pathogenic mechanisms involve excitotoxicity (glutamate accumulation), mitochondrial dysfunction, protein misfolding (SOD1, TDP-43, FUS), neuroinflammation, and non-cell-autonomous effects from glial cells. Neurogenic stem cells (derived from neural progenitor populations or induced pluripotent stem cells differentiated toward motor-neuron lineage) and placental mesenchymal stem cells deliver neuroprotective factors (GDNF, BDNF, HGF), suppress harmful microglial activation, and stabilise neuromuscular junctions. Sixty-five registered trials and ten actively recruiting centres explore intrathecal or intravenous cell delivery in rapidly progressive or early-onset ALS populations.
| Indikative Kosten · Bulgarien (EU) | €3,000–€8,000 |
|---|---|
| Globale Marktkostenfalle | €19,100–€24,000 (bookinghealth.com) |
| Wichtigste untersuchte Zelltypen | Neurogenic Cells, MSCs from Amniotic Membrane |
| Genehmigungsstatus | Experimentell |
| Registrierte Studien (ClinicalTrials.gov) | 65 · 10 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
Clinical trial safety data across >500 ALS recipients shows no treatment-limiting adverse events from intrathecal or intravenous cell infusion. Efficacy signals emerge from small phase II cohorts: decline in ALSFRS-R (disease rating scale) is slowed by 30–50% over 12 months in 30–45% of treated patients versus untreated historical controls; some maintain muscle strength for 6–12 months longer than expected disease trajectory. Markers of neuroinflammation (CSF cytokine levels, microglial activation on PET imaging) decline in responder subgroups. No completed pivotal trial has demonstrated survival prolongation; two large multi-centre efficacy trials are recruiting.
Depending on assessment, a ALS (Motor Neurone Disease) protocol may draw on:
ALS stem-cell protocols in Sofia and international centres range €7,000–11,000 for treatment courses, incorporating 1–3 intrathecal cell injections (requiring lumbar puncture or reservoir implantation), baseline and serial neurological assessment (ALSFRS-R, manual muscle strength testing, respiratory function testing), neuroimaging (brain/spine MRI), and neurology consultation. Intrathecal procedures carry infection and neurological risks; surveillance and specialist neurologist involvement are mandatory. Repeat treatments and extended follow-up imaging accumulate costs substantially.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the ALS (Motor Neurone Disease) cost-by-country breakdown, or compare the best countries for ALS (Motor Neurone Disease) →
Vor der Buchung prüfen: Sicherheit & Regulierung, das Erholungsklima, ob Sie geeignet sind, und welcher Zelltyp zu ALS (Motor Neurone Disease) passt.
Vollständiges ALS (Amyotrophe Lateralsklerose) FAQ → · ALS (Amyotrophe Lateralsklerose) Kostenaufschlüsselung →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Bin ich geeignet? · Welcher Zelltyp? · Types of clinics & best countries · Kostenrechner
Medizinisch geprüft vom Redaktionsteam von StemCellAtlas zusammen mit Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) der Partnerklinik Stem Plus (Sofia), gemäß ISSCR-, FDA- und EMA-Leitlinien. Educational information, not medical advice; figures indicative.
GMP-zertifizierte regenerative Medizin mitten in der EU — ab 3.000–8.000 €, ein Bruchteil der US- oder Deutschland-Preise. Individuelle Protokolle für internationale Patienten aus über 50 Ländern.
Kostenlose ärztliche Prüfung